United Therapeutics Corporation
UTHR
$301.50
$2.080.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.15% | 15.25% | 21.35% | 23.46% | 22.71% |
| Total Depreciation and Amortization | 31.30% | 40.80% | 36.28% | 26.19% | 16.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.70% | 145.04% | 216.67% | 10.32% | -1.20% |
| Change in Net Operating Assets | -1.31% | 88.12% | 38.45% | -57.29% | 22.08% |
| Cash from Operations | 24.03% | 44.11% | 35.70% | 18.95% | 27.39% |
| Capital Expenditure | -31.88% | -24.59% | -6.99% | -24.74% | -17.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.41% | -136.07% | 265.93% | 219.79% | 230.45% |
| Cash from Investing | -282.99% | -303.89% | 157.98% | 161.25% | 152.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -133.33% | -100.00% | -300.00% | -- | -- |
| Issuance of Common Stock | -10.41% | 57.74% | 53.06% | -7.20% | -25.61% |
| Repurchase of Common Stock | 97.90% | 98.41% | -7,234.78% | -7,286.86% | -7,231.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -325.93% | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash from Financing | 64.10% | 75.14% | -10,444.54% | -1,033.21% | -984.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.68% | 636.82% | 98.58% | 216.68% | 5.99% |